SK12372001A3 - Použitie pde4 špecifického inhibítora a spôsob profylaxie a liečby copd - Google Patents

Použitie pde4 špecifického inhibítora a spôsob profylaxie a liečby copd Download PDF

Info

Publication number
SK12372001A3
SK12372001A3 SK1237-2001A SK12372001A SK12372001A3 SK 12372001 A3 SK12372001 A3 SK 12372001A3 SK 12372001 A SK12372001 A SK 12372001A SK 12372001 A3 SK12372001 A3 SK 12372001A3
Authority
SK
Slovakia
Prior art keywords
pde
rolipram
ratio
compounds
binding
Prior art date
Application number
SK1237-2001A
Other languages
English (en)
Slovak (sk)
Inventor
Siegfried B. Christensen
Mary S. Barnette
Theodore J. Torphy
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SK12372001A3 publication Critical patent/SK12372001A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1237-2001A 1999-03-01 2000-03-01 Použitie pde4 špecifického inhibítora a spôsob profylaxie a liečby copd SK12372001A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12231599P 1999-03-01 1999-03-01
PCT/US2000/005227 WO2000051598A1 (en) 1999-03-01 2000-03-01 Method for treating copd

Publications (1)

Publication Number Publication Date
SK12372001A3 true SK12372001A3 (sk) 2001-12-03

Family

ID=22401990

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1237-2001A SK12372001A3 (sk) 1999-03-01 2000-03-01 Použitie pde4 špecifického inhibítora a spôsob profylaxie a liečby copd

Country Status (30)

Country Link
US (1) US6670394B1 (de)
EP (1) EP1156799A4 (de)
JP (1) JP2002538114A (de)
KR (1) KR20010102459A (de)
CN (1) CN1349403A (de)
AP (1) AP2001002248A0 (de)
AR (1) AR042369A1 (de)
AU (1) AU772583B2 (de)
BG (1) BG105953A (de)
BR (1) BR0008603A (de)
CA (1) CA2366036A1 (de)
CO (1) CO5160248A1 (de)
CZ (1) CZ20013149A3 (de)
DZ (1) DZ3019A1 (de)
EA (1) EA200100930A1 (de)
HK (1) HK1043935A1 (de)
HU (1) HUP0200288A3 (de)
ID (1) ID29888A (de)
IL (1) IL144992A0 (de)
MA (1) MA25522A1 (de)
NO (1) NO20014222L (de)
NZ (1) NZ513695A (de)
OA (1) OA11842A (de)
PE (1) PE20001505A1 (de)
PL (1) PL352816A1 (de)
SK (1) SK12372001A3 (de)
TR (1) TR200102514T2 (de)
UY (1) UY26040A1 (de)
WO (1) WO2000051598A1 (de)
ZA (1) ZA200107186B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
AR029984A1 (es) * 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
JPWO2004087148A1 (ja) * 2003-03-31 2006-06-29 協和醗酵工業株式会社 肺疾患の治療および／または予防剤
JPWO2005056009A1 (ja) * 2003-12-12 2007-07-05 協和醗酵工業株式会社 肺疾患治療剤
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP1861074B1 (de) 2005-03-16 2013-04-24 Takeda GmbH Geschmacksmaskierte dosierform von roflumilast
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019751A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
DE69433997T2 (de) 1993-06-18 2005-01-27 Smithkline Beecham Corp. Verfahren zur Identifizierung eines PDE IV Hemmers
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DK0730588T3 (da) * 1993-11-26 1997-12-08 Pfizer Isoxazolinforbindelser som antiinflammatoriske midler
UY25338A1 (es) 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd

Also Published As

Publication number Publication date
TR200102514T2 (tr) 2002-04-22
AP2001002248A0 (en) 2001-09-30
BG105953A (en) 2002-05-31
HUP0200288A3 (en) 2003-08-28
CN1349403A (zh) 2002-05-15
PE20001505A1 (es) 2001-02-08
PL352816A1 (en) 2003-09-08
ZA200107186B (en) 2002-08-30
WO2000051598A1 (en) 2000-09-08
US6670394B1 (en) 2003-12-30
EA200100930A1 (ru) 2002-02-28
ID29888A (id) 2001-10-18
MA25522A1 (fr) 2002-10-01
NO20014222D0 (no) 2001-08-31
DZ3019A1 (fr) 2005-05-20
NO20014222L (no) 2001-10-29
JP2002538114A (ja) 2002-11-12
CA2366036A1 (en) 2000-09-08
EP1156799A1 (de) 2001-11-28
NZ513695A (en) 2001-09-28
CO5160248A1 (es) 2002-05-30
BR0008603A (pt) 2001-12-26
KR20010102459A (ko) 2001-11-15
IL144992A0 (en) 2002-06-30
OA11842A (en) 2005-08-22
HUP0200288A2 (hu) 2002-05-29
AU772583B2 (en) 2004-04-29
HK1043935A1 (zh) 2002-10-04
CZ20013149A3 (cs) 2002-04-17
EP1156799A4 (de) 2004-11-10
AR042369A1 (es) 2005-06-22
UY26040A1 (es) 2000-09-29
AU3386900A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
US5998428A (en) Compounds and methods for treating PDE IV-related diseases
CZ20013148A3 (cs) Léčivo pro prevenci nebo léčbu tělesným pohybem vyvolaného astmatu, astmatu vyvolaného chladným vzduchem nebo astmatu vyvolaného znečiątěním ľivotního prostředí
EP1908461B9 (de) Verwendung des Enantiomers (1S, 2R) von Milnacipran zur Herstellung eines Arzneimittels
Sastre et al. Post mortem redistribution of drugs: current state of knowledge
Rogers et al. E2020—the pharmacology of a piperidine cholinesterase inhibitor
PT1928438E (pt) Método para tratamento de dependências de drogas e comportamentos
SK12372001A3 (sk) Použitie pde4 špecifického inhibítora a spôsob profylaxie a liečby copd
Giacobini Cholinesterase inhibitors do more than inhibit cholinesterase
Lee et al. Selective muscarinic receptor antagonists for airway diseases
KR20010050225A (ko) 포유동물에서의 니코틴 탐닉의 예방 및 치료를 위한 약학조성물
EP0710109B1 (de) Verfahren zur Identifizierung eines PDE IV Hemmers
Nutt et al. Treatment of Huntington disease with a cholinergic agonist
JP2002543133A (ja) ロフルミラストおよびｐｄｅ−３インヒビターを含有する共力薬の組合せ物
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
EP2528595A1 (de) Verbindungen zur verwendung bei der behandlung von erkrankungen
Dean et al. Effects of ethanol on cocaine metabolism and disposition in the rat
Mokrý et al. Effects of Selective Inhibition of PDE4 by YM976 on airway reactivity and cough in ovalbumin-sensitized guinea pigs
NZ243577A (en) Synergistic anti-hypertensive composition containing tetrahydronaphthalene and pyridodiazepine derivatives
MXPA01008853A (en) Method for treating copd
Brown et al. Interactions of pyrazole and ethanol on norepinephrine metabolism in rat brain.
RU2607946C2 (ru) Композиции, включающие ингибитор холинэстеразы, для лечения когнитивных расстройств
US20020115111A1 (en) Compounds
ZA200107187B (en) Method for treating exercise induced asthma.
MXPA01008858A (en) Method for treating exercise induced asthma
Gessner et al. The disulfiram-ethanol reaction